In this study, we confirmed that both 64Cu-cudotadipep and 64Cu-cunotadipep, which are newly developed PSMA-targeted radiopharmaceuticals, accumulate in PSMA-expressing prostate cancer cells. This evidence concerns the gene FOLH1 and prostate carcinoma.